BERSANELLI, MELISSA
BERSANELLI, MELISSA
Dipartimento di Medicina e Chirurgia
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)
2022-01-01 Stellato, M.; Buti, S.; Maruzzo, M.; Bersanelli, M.; Ermacora, P.; Maiorano, B. A.; Prati, V.; De Giorgi, U. F. F.; Pierantoni, F.; Malgeri, A.; Mennitto, A.; Cavo, A.; Vitale, M. G.; Santoni, M.; Carella, C.; Procopio, G.; Verzoni, E.; Santini, D.
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer
2011-01-01 Tiseo, M.; Gelsomino, F.; Bartolotti, M.; Bordi, P.; Bersanelli, Melissa; Rossi, G.; Ardizzoni, A.
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
2020-01-01 Cortellini, A.; Bersanelli, M.; Santini, D.; Buti, S.; Tiseo, M.; Cannita, K.; Perrone, F.; Giusti, R.; De Tursi, M.; Zoratto, F.; Marconcini, R.; Russano, M.; Zeppola, T.; Anesi, C.; Filetti, M.; Marchetti, P.; Botticelli, A.; Gelibter, A.; De Galitiis, F.; Vitale, M. G.; Rastelli, F.; Tudini, M.; Silva, R. R.; Atzori, F.; Chiari, R.; Ricciuti, B.; De Giglio, A.; Migliorino, M. R.; Mallardo, D.; Vanella, V.; Mosillo, C.; Bracarda, S.; Rinaldi, S.; Berardi, R.; Natoli, C.; Ficorella, C.; Porzio, G.; Ascierto, P. A.
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
2021-01-01 Roviello, G.; Buti, S.; Cattrini, C.; Mennitto, A.; Messina, C.; Airoldi, C.; Vannini, G.; Bersanelli, M.
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade
2022-01-01 Takada, Kazuki; Buti, Sebastiano; Bersanelli, Melissa; Shimokawa, Mototsugu; Takamori, Shinkichi; Matsubara, Taichi; Takenaka, Tomoyoshi; Okamoto, Tatsuro; Hamatake, Motoharu; Tsuchiya-Kawano, Yuko; Otsubo, Kohei; Nakanishi, Yoichi; Okamoto, Isamu; Pinato, David J.; Cortellini, Alessio; Yoshizumi, Tomoharu
Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients
2012-01-01 Tiseo, M.; Bersanelli, M.; Barili, M. P.; Bartolotti, M.; De Luca, G.; Gelsomino, F.; Camisa, R.; Cademartiri, F.; Ardizzoni, A.
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6)
2020-01-01 Buti, S.; Karakiewicz, P. I.; Bersanelli, M.; Capitanio, U.; Tian, Z.; Cortellini, A.; Taguchi, S.; Briganti, A.; Montorsi, F.; Leonardi, F.; Bandini, M.
Autophagic gene polymorphisms in liquid biopsies and outcome of patients with metastatic clear cell renal cell carcinoma
2018-01-01 Santoni, M.; Piva, F.; De Giorgi, U.; Mosca, A.; Basso, U.; Santini, D.; Buti, S.; Lolli, C.; Terrone, C.; Maruzzo, M.; Iuliani, M.; Bersanelli, M.; Conti, A.; Mazzucchelli, R.; Montironi, R.; Burattini, L.; Berardi, R.
Avelumab Maintenance for Urothelial Carcinoma
2020-01-01 Buti, S.; Bersanelli, M.
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?
2017-01-01 Taguchi, S.; Buti, S.; Fukuhara, H.; Otsuka, M.; Bersanelli, M.; Morikawa, T.; Miyazaki, H.; Nakagawa, T.; Fujimura, T.; Kume, H.; Igawa, Y.; Homma, Y.
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect?
2014-01-01 Buti, S.; Bersanelli, M.; Tiseo, M.; Ardizzoni, A.; Musolino, A.
Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential
2017-01-01 Bersanelli, M.; Buti, S.
Cabozantinib in RCC: only a METEOR or a rising star?
2016-01-01 Buti, S; Bersanelli, M
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis
2021-01-01 Buti, Sebastiano; Bersanelli, Melissa; Mazzaschi, Giulia; Cattrini, Carlo; Brunelli, Matteo; Maio, Massimo Di
Capter 4 - Adjuvant Therapy for Renal Cell Carcinoma
2012-01-01 Buti, S; Bersanelli, M; Donini, M; Ardizzoni, A
Chemotherapy in metastatic renal cell carcinoma today? A systematic review
2013-01-01 Buti, S.; Bersanelli, M.; Sikokis, A.; Maines, F.; Facchinetti, F.; Bria, E.; Ardizzoni, A.; Tortora, G.; Massari, F.
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
2020-01-01 Bersanelli, M.; Buti, S.; Giannarelli, D.; Leonetti, A.; Cortellini, A.; Russo, G. L.; Signorelli, D.; Toschi, L.; Milella, M.; Pilotto, S.; Bria, E.; Proto, C.; Marinello, A.; Randon, G.; Rossi, S.; Vita, E.; Sartori, G.; D'Argento, E.; Qako, E.; Giaiacopi, E.; Ghilardi, L.; Bettini, A. C.; Rapacchi, E.; Mazzoni, F.; Lavacchi, D.; Scotti, V.; Ciccone, L. P.; De Tursi, M.; Di Marino, P.; Santini, D.; Russano, M.; Bordi, P.; Di Maio, M.; Audisio, M.; Filetti, M.; Giusti, R.; Berardi, R.; Fiordoliva, I.; Cerea, G.; Pizzutilo, E. G.; Bearz, A.; De Carlo, E.; Cecere, F.; Renna, D.; Camisa, R.; Caruso, G.; Ficorella, C.; Banna, G. L.; Cortinovis, D.; Brighenti, M.; Garassino, M. C.; Tiseo, M.
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab
2017-01-01 Tiseo, M.; Facchinetti, F.; Buti, S.; Gelsomino, F.; Veneziani, M.; Squadrilli, A.; Bordi, P.; Bersanelli, M.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mazzaschi, G.; Leonardi, F.; Quaini, F.; Ardizzoni, A.; Missale, G.
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab
2018-01-01 Facchinetti, F.; Veneziani, M.; Buti, S.; Gelsomino, F.; Squadrilli, A.; Bordi, P.; Bersanelli, M.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mazzaschi, G.; Leonardi, F.; Quaini, F.; Ardizzoni, A.; Missale, G.; Tiseo, M.
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy
2020-01-01 Bersanelli, M.; Zielli, T.; Perrone, F.; Casartelli, C.; Prattico, F.; Rapacchi, E.; Camisa, R.; Tognetto, M.; Clemente, A.; Giannarelli, D.; Rebuzzi, S. E.; Leonetti, A.; Bordi, P.; Tiseo, M.; Buti, S.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) | 1-gen-2022 | Stellato, M.; Buti, S.; Maruzzo, M.; Bersanelli, M.; Ermacora, P.; Maiorano, B. A.; Prati, V.; De Giorgi, U. F. F.; Pierantoni, F.; Malgeri, A.; Mennitto, A.; Cavo, A.; Vitale, M. G.; Santoni, M.; Carella, C.; Procopio, G.; Verzoni, E.; Santini, D. | |
| Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer | 1-gen-2011 | Tiseo, M.; Gelsomino, F.; Bartolotti, M.; Bordi, P.; Bersanelli, Melissa; Rossi, G.; Ardizzoni, A. | |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events | 1-gen-2020 | Cortellini, A.; Bersanelli, M.; Santini, D.; Buti, S.; Tiseo, M.; Cannita, K.; Perrone, F.; Giusti, R.; De Tursi, M.; Zoratto, F.; Marconcini, R.; Russano, M.; Zeppola, T.; Anesi, C.; Filetti, M.; Marchetti, P.; Botticelli, A.; Gelibter, A.; De Galitiis, F.; Vitale, M. G.; Rastelli, F.; Tudini, M.; Silva, R. R.; Atzori, F.; Chiari, R.; Ricciuti, B.; De Giglio, A.; Migliorino, M. R.; Mallardo, D.; Vanella, V.; Mosillo, C.; Bracarda, S.; Rinaldi, S.; Berardi, R.; Natoli, C.; Ficorella, C.; Porzio, G.; Ascierto, P. A. | |
| Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? | 1-gen-2021 | Roviello, G.; Buti, S.; Cattrini, C.; Mennitto, A.; Messina, C.; Airoldi, C.; Vannini, G.; Bersanelli, M. | |
| Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade | 1-gen-2022 | Takada, Kazuki; Buti, Sebastiano; Bersanelli, Melissa; Shimokawa, Mototsugu; Takamori, Shinkichi; Matsubara, Taichi; Takenaka, Tomoyoshi; Okamoto, Tatsuro; Hamatake, Motoharu; Tsuchiya-Kawano, Yuko; Otsubo, Kohei; Nakanishi, Yoichi; Okamoto, Isamu; Pinato, David J.; Cortellini, Alessio; Yoshizumi, Tomoharu | |
| Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients | 1-gen-2012 | Tiseo, M.; Bersanelli, M.; Barili, M. P.; Bartolotti, M.; De Luca, G.; Gelsomino, F.; Camisa, R.; Cademartiri, F.; Ardizzoni, A. | |
| Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) | 1-gen-2020 | Buti, S.; Karakiewicz, P. I.; Bersanelli, M.; Capitanio, U.; Tian, Z.; Cortellini, A.; Taguchi, S.; Briganti, A.; Montorsi, F.; Leonardi, F.; Bandini, M. | |
| Autophagic gene polymorphisms in liquid biopsies and outcome of patients with metastatic clear cell renal cell carcinoma | 1-gen-2018 | Santoni, M.; Piva, F.; De Giorgi, U.; Mosca, A.; Basso, U.; Santini, D.; Buti, S.; Lolli, C.; Terrone, C.; Maruzzo, M.; Iuliani, M.; Bersanelli, M.; Conti, A.; Mazzucchelli, R.; Montironi, R.; Burattini, L.; Berardi, R. | |
| Avelumab Maintenance for Urothelial Carcinoma | 1-gen-2020 | Buti, S.; Bersanelli, M. | |
| Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? | 1-gen-2017 | Taguchi, S.; Buti, S.; Fukuhara, H.; Otsuka, M.; Bersanelli, M.; Morikawa, T.; Miyazaki, H.; Nakagawa, T.; Fujimura, T.; Kume, H.; Igawa, Y.; Homma, Y. | |
| BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? | 1-gen-2014 | Buti, S.; Bersanelli, M.; Tiseo, M.; Ardizzoni, A.; Musolino, A. | |
| Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential | 1-gen-2017 | Bersanelli, M.; Buti, S. | |
| Cabozantinib in RCC: only a METEOR or a rising star? | 1-gen-2016 | Buti, S; Bersanelli, M | |
| Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis | 1-gen-2021 | Buti, Sebastiano; Bersanelli, Melissa; Mazzaschi, Giulia; Cattrini, Carlo; Brunelli, Matteo; Maio, Massimo Di | |
| Capter 4 - Adjuvant Therapy for Renal Cell Carcinoma | 1-gen-2012 | Buti, S; Bersanelli, M; Donini, M; Ardizzoni, A | |
| Chemotherapy in metastatic renal cell carcinoma today? A systematic review | 1-gen-2013 | Buti, S.; Bersanelli, M.; Sikokis, A.; Maines, F.; Facchinetti, F.; Bria, E.; Ardizzoni, A.; Tortora, G.; Massari, F. | |
| Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study | 1-gen-2020 | Bersanelli, M.; Buti, S.; Giannarelli, D.; Leonetti, A.; Cortellini, A.; Russo, G. L.; Signorelli, D.; Toschi, L.; Milella, M.; Pilotto, S.; Bria, E.; Proto, C.; Marinello, A.; Randon, G.; Rossi, S.; Vita, E.; Sartori, G.; D'Argento, E.; Qako, E.; Giaiacopi, E.; Ghilardi, L.; Bettini, A. C.; Rapacchi, E.; Mazzoni, F.; Lavacchi, D.; Scotti, V.; Ciccone, L. P.; De Tursi, M.; Di Marino, P.; Santini, D.; Russano, M.; Bordi, P.; Di Maio, M.; Audisio, M.; Filetti, M.; Giusti, R.; Berardi, R.; Fiordoliva, I.; Cerea, G.; Pizzutilo, E. G.; Bearz, A.; De Carlo, E.; Cecere, F.; Renna, D.; Camisa, R.; Caruso, G.; Ficorella, C.; Banna, G. L.; Cortinovis, D.; Brighenti, M.; Garassino, M. C.; Tiseo, M. | |
| Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab | 1-gen-2017 | Tiseo, M.; Facchinetti, F.; Buti, S.; Gelsomino, F.; Veneziani, M.; Squadrilli, A.; Bordi, P.; Bersanelli, M.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mazzaschi, G.; Leonardi, F.; Quaini, F.; Ardizzoni, A.; Missale, G. | |
| Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab | 1-gen-2018 | Facchinetti, F.; Veneziani, M.; Buti, S.; Gelsomino, F.; Squadrilli, A.; Bordi, P.; Bersanelli, M.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mazzaschi, G.; Leonardi, F.; Quaini, F.; Ardizzoni, A.; Missale, G.; Tiseo, M. | |
| Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy | 1-gen-2020 | Bersanelli, M.; Zielli, T.; Perrone, F.; Casartelli, C.; Prattico, F.; Rapacchi, E.; Camisa, R.; Tognetto, M.; Clemente, A.; Giannarelli, D.; Rebuzzi, S. E.; Leonetti, A.; Bordi, P.; Tiseo, M.; Buti, S. |